Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD1305 QTcF loading dose versus steady-state study in patients with documented atrial fibrillation
2007-007058-79Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Atrial fibrillation (AFib) comparing AZD1305 extended-release tablets with Placebo (2 arms). Primary endpoint: QTcF interval. Started Dec 2007; status: completed.
02
Drugs
AZD-1305
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on 2007-007058-79.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-007058-79.